Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well it held up today. I really didnt see the same MM shinanigans today that we have seen in the previous sessions.
are we expecting any more announcements this week?????
wooooohooooooooooooo I subscribed, not feeling good about it because I really dont trust matt, but what the hay.
the company should have made sure they acutally had the domains before releasing that PR
there is absolutely nothing for FTG to be nervous about
yes they are already making big money
this really could be huge, with huge revenue potential. this company is already way in the black with building revenues
has anyone taken a look at this???
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 10% of this market, or, $43.56 million dollars in its next two market years, and expects to meet this goal. Its primary competition is from drug companies. Drug therapy has proven far less successful, and is prone to side-effects and addiction issues.
yup just watching to see if the "games" are finshed
briner was properly served and is now in default.
Morning all RBRM news here
ReBuilder Medical Technologies, Inc. Announces Its Securities Have Been Cleared For Quotation on the Pink Sheets
Jul 18, 2007 9:00:00 AM
CHARLES TOWN, W.Va., July 18 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), an emerging medical manufacturer of innovative technologies founded by world-renowned medical device inventor Dr. David B. Phillips, announced today that its securities have been cleared for public quotation on the Pink Sheets under the symbol RBRM.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
ReBuilder Medical's flagship product is its FDA registered, ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical device that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
Over 20,000 patients have been treated using the cutting-edge technology of the ReBuilder System. It has a success rate that tops 95% and treats the cause as well as the symptoms. The treatment can be self-administered for less than $1.00 a day.
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 10% of this market, or, $43.56 million dollars in its next two market years, and expects to meet this goal. Its primary competition is from drug companies. Drug therapy has proven far less successful, and is prone to side-effects and addiction issues.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum virus without any side effects. The company is currently performing research and development on a number of other medical products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the Early Detection of Breast Cancer (1980) and the AcuPen which detects acupuncture points electronically, and then treats them.
Dr. Phillips said, "We have seen significant growth in ReBuilder Medical over the past several years and public quotation was a logical step for us. We constantly develop our products to ensure they successfully alleviate the symptoms of peripheral neuropathy and molluscum contagiosum and public quotation will ensure that we are able to progress in our mission to help those suffering from those diseases."
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE ReBuilder Medical Technologies, Inc.
----------------------------------------------
David Phillips of ReBuilder Medical Technologies
Inc.
+1-304-725-2202
RBRM news
ReBuilder Medical Technologies, Inc. Announces Its Securities Have Been Cleared For Quotation on the Pink Sheets
Jul 18, 2007 9:00:00 AM
CHARLES TOWN, W.Va., July 18 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), an emerging medical manufacturer of innovative technologies founded by world-renowned medical device inventor Dr. David B. Phillips, announced today that its securities have been cleared for public quotation on the Pink Sheets under the symbol RBRM.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
ReBuilder Medical's flagship product is its FDA registered, ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical device that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
Over 20,000 patients have been treated using the cutting-edge technology of the ReBuilder System. It has a success rate that tops 95% and treats the cause as well as the symptoms. The treatment can be self-administered for less than $1.00 a day.
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 10% of this market, or, $43.56 million dollars in its next two market years, and expects to meet this goal. Its primary competition is from drug companies. Drug therapy has proven far less successful, and is prone to side-effects and addiction issues.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum virus without any side effects. The company is currently performing research and development on a number of other medical products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the Early Detection of Breast Cancer (1980) and the AcuPen which detects acupuncture points electronically, and then treats them.
Dr. Phillips said, "We have seen significant growth in ReBuilder Medical over the past several years and public quotation was a logical step for us. We constantly develop our products to ensure they successfully alleviate the symptoms of peripheral neuropathy and molluscum contagiosum and public quotation will ensure that we are able to progress in our mission to help those suffering from those diseases."
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE ReBuilder Medical Technologies, Inc.
----------------------------------------------
David Phillips of ReBuilder Medical Technologies
Inc.
+1-304-725-2202
NEWS OUT
ReBuilder Medical Technologies, Inc. Announces Its Securities Have Been Cleared For Quotation on the Pink Sheets
Jul 18, 2007 9:00:00 AM
CHARLES TOWN, W.Va., July 18 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), an emerging medical manufacturer of innovative technologies founded by world-renowned medical device inventor Dr. David B. Phillips, announced today that its securities have been cleared for public quotation on the Pink Sheets under the symbol RBRM.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
ReBuilder Medical's flagship product is its FDA registered, ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical device that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
Over 20,000 patients have been treated using the cutting-edge technology of the ReBuilder System. It has a success rate that tops 95% and treats the cause as well as the symptoms. The treatment can be self-administered for less than $1.00 a day.
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 10% of this market, or, $43.56 million dollars in its next two market years, and expects to meet this goal. Its primary competition is from drug companies. Drug therapy has proven far less successful, and is prone to side-effects and addiction issues.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum virus without any side effects. The company is currently performing research and development on a number of other medical products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the Early Detection of Breast Cancer (1980) and the AcuPen which detects acupuncture points electronically, and then treats them.
Dr. Phillips said, "We have seen significant growth in ReBuilder Medical over the past several years and public quotation was a logical step for us. We constantly develop our products to ensure they successfully alleviate the symptoms of peripheral neuropathy and molluscum contagiosum and public quotation will ensure that we are able to progress in our mission to help those suffering from those diseases."
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
SOURCE ReBuilder Medical Technologies, Inc.
----------------------------------------------
David Phillips of ReBuilder Medical Technologies
Inc.
+1-304-725-2202
this is a scam run by drew
call king ricky
someone is dumping
the stock is a steal
I am hearing rumors about an announcement soon
leopard sit tight, something is happening right now
and PSPJ is looking to be the next big gainer.
64 x 66 open lets goooooooooooooooooooooooooo
I saw this guy on TV!!!!!!! hmmmmm this could be an interesting play
red light, THIS IS A PUBLIC COMPANY,,, HELLOOOOOOOOOOOOOOOO. It has to make money. I dont give a crapola if they only sell bobby hull memorabelia and forget the hocky the season. THEY HAVE TO MAKE MONEY. U have any idea how much money smith blew through last year?????? To field teams in podunk towns??????
THATS NOT GOING TO HAPPEN THIS YEAR
the fact is Osoyoos is a money losing proposition no matter how you look at it. me as a MAJOR shareholder have already strongly ( Including some foul language) expressed my views on this subject. I for one, WILL NOT TOLERATE another money losing season.
looks like we could have a big day today, GO PSPJ!!!!!!!!!!!
can u give us an example of what may have gone wrong with a wire transfer????? the only thing I can think of is insuffecient funds. can you think of anything else???
not a bad day at all. could have done without that silly market order this morning, but all in all not bad considering
excuse me but thats not correct either. I lived and worked overseas and US taxes are STILL collected
absolutely!!!!!
excuse me but one of the posters said that its a tax advantage to take your payment on a debit card
thank you, thats exactly what the IRS enforcement officer told me this morning
If payment is made via a debit card. On what system will a person be able to access to draw funds? ( Cirrus, Maestro, Star ETC ETC?) Any ATM? A certain bank ATM? What will the charges be to withdraw funds? who will get those access fees? If I sold something I would want to get FULL value not something that gets diluted with access fees.
1-800-829-1040
Ok I just got off the phone with IRS compliance and enforcement. I laid out the scenario described in the post. I was told that it would not matter, for a US citizen the full taxes would be owed. They inquired about the company making these claims and I told them it was related to panamersa and gave them the contact number.... I suggest you all call IRS enforcement and find out for yourselves.
thats true, but for anyone to hint that this is a tax free transaction, is absolutely false
that would be tax fraud. To the IRS it wont matter that the funds are offshore
u dont believe that right? just because the money is offshore means nothing. taxes are owed no matter where a us citezen makes or keeps their money
what do u mean by " not in wire form"
now its on to the judgement!!!!!!!!!!!!!!!!!!!!!!
PSPJ is looking real good. Alot of celebrity faces here